Eiger BioPharmaceuticals, Inc.
Case Number:
8:24-bk-80040
Court:
Nature of Suit:
Firms
Companies
Sectors & Industries:
-
August 20, 2024
Lender's $13M Atty Fee Reserve Bid In Eiger Ch. 11 Plan Nixed
A Texas bankruptcy judge on Tuesday mostly sided with life science company Eiger BioPharmaceuticals in estimating a secured lender's future claims, saying at a hearing that Eiger's Chapter 11 reserve for the claim should include two years worth of interest and agreeing that $1 million should be earmarked for legal fees, not the lender's requested $13 million sum.
-
June 26, 2024
Eiger Gets OK On Ch. 11 Drug Sale After Tripling Initial Bid
A Texas bankruptcy judge on Wednesday approved Eiger BioPharmaceuticals' $35.1 million sale of its Avexitide product, after the drug company more than tripled an initial bid for the metabolic-disease treatment during a recent auction.
-
May 29, 2024
Drug Co. Eiger Can Probe Lender On Foiled PIPE Deal Fallout
Eiger BioPharmaceuticals received a Texas bankruptcy judge's approval Wednesday to collect documents from lender Innovatus Life Sciences tied to what the rare-disease drugmaker called Innovatus's decision to "manufacture" a default under a credit agreement, a move that allegedly blew up a potential financing deal and precipitated Eiger's Chapter 11 filing.
-
May 03, 2024
Biotech Eiger Says Ch. 11 Should Stay In Texas
Rare-disease treatment developer Eiger has urged a Texas bankruptcy judge to keep its Chapter 11 in the Dallas court despite an attempt by the U.S. Trustee's Office to have the case transferred to Delaware or California, asserting that it is a virtual business with its closest physical ties in Texas.
-
May 01, 2024
Eiger Gets Deal With Merck Over $46M Rare-Disease Drug Sale
Bankrupt Eiger BioPharmaceuticals Inc. told a Texas federal judge Wednesday it had struck a tentative agreement with drug company Merck & Co. over licensing rights to a rare-disease drug that it is selling for $46.1 million.
-
April 29, 2024
ABI's New Prez, Scammers Charged, Giuliani To Appeal
The American Bankruptcy Institute named Polsinelli attorney Christopher A. Ward as its new president, the Office of the United States Trustee charged two with fraud for petition preparation services, and Rudy Giuliani asked a New York judge for permission to appeal his $148 million defamation verdict to the D.C. Circuit.
-
April 23, 2024
Biotech Eiger Can Sell Rare-Disease Drug For $46M In Ch. 11
Insolvent biotechnology company Eiger BioPharmaceuticals Inc. received approval Tuesday at a hearing in Texas to sell its drug treatment for a rare genetic disorder to Sentynl Therapeutics, a subsidiary of Indian drugmaker Zydus Lifesciences, for $46.1 million.
-
April 15, 2024
US Trustee Wants Biotech Eiger's Ch. 11 Booted From Texas
The U.S. Trustee's Office has asked a Texas bankruptcy judge to remove the Chapter 11 case of Eiger BioPharmaceuticals Inc. from the Lone Star State, saying the company cannot justify bringing it there.
-
April 03, 2024
Biotech Eiger Can Take Sentynl's Improved Drug Bid In Ch. 11
Eiger BioPharmaceuticals Inc. received approval Wednesday to select a $30 million base offer for its Zokinvy drug and use cash collateral after a Texas bankruptcy judge dismissed objections to the relief, allowing the company to move ahead with a planned auction for its rare-disease treatments.
-
April 01, 2024
Eiger BioPharmaceuticals Hits Ch. 11 With $53.1M Debt
Eiger BioPharmaceuticals Inc. filed for Chapter 11 protection in Texas bankruptcy court Monday with $53.1 million of debt and plans to sell its assets during the case.